Get the Stockscreener App
0.9796
7.65%
0.0696
Werewolf Therapeutics Inc stock is traded at $0.9796, with a volume of 704.63K.
It is up +7.65% in the last 24 hours and down -0.24% over the past month.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. It has one reportable segment, which focuses on the discovery and development of cancer therapeutics.
See More
Previous Close:
$0.91
Open:
$0.93
24h Volume:
704.63K
Relative Volume:
1.28
Market Cap:
$47.61M
Revenue:
$1.14M
Net Income/Loss:
$-56.27M
P/E Ratio:
-0.807
EPS:
-1.2139
Net Cash Flow:
$-51.94M
1W Performance:
+5.33%
1M Performance:
-0.24%
6M Performance:
+15.38%
1Y Performance:
-39.90%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.907
$0.99
52-Week Range:
$0.27
$1.9371
Werewolf Therapeutics Inc Stock (HOWL) Company Profile
Name
Werewolf Therapeutics Inc
Sector
Industry
Phone
617-952-0555
Address
200 TALCOTT AVENUE, WATERTOWN
Compare HOWL vs VRTX, MRNA, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HOWL
Werewolf Therapeutics Inc
|
0.9796 | 47.61M | 1.14M | -56.27M | -51.94M | -1.2139 |
VRTX
Vertex Pharmaceuticals Inc
|
510.08 | 129.29B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
225.00 | 89.83B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
746.54 | 76.86B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
825.03 | 51.88B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.76 | 40.67B | 742.00K | -1.37B | -1.07B | -7.0731 |
Werewolf Therapeutics Inc Stock (HOWL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-25 | Downgrade | Wedbush | Outperform → Neutral |
| Apr-03-24 | Initiated | JMP Securities | Mkt Outperform |
| Aug-24-23 | Initiated | Wedbush | Outperform |
| Jun-06-23 | Resumed | Jefferies | Buy |
| Sep-10-21 | Initiated | BofA Securities | Buy |
| May-25-21 | Initiated | Evercore ISI | Outperform |
| May-25-21 | Initiated | H.C. Wainwright | Buy |
| May-25-21 | Initiated | Jefferies | Buy |
| May-25-21 | Initiated | SVB Leerink | Outperform |
View All
Werewolf Therapeutics Inc Stock (HOWL) Latest News
New Strong Buy Stocks for October 9th - Zacks Investment Research
Scienture Holdings, Inc. (SCNX) Stock Price & News - Syfe
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), Lantheus Holdings Inc. (Nasdaq – LNTH), MarketAxess Holdings Inc. ( - mykxlg.com
Kairos Pharma, Ltd. (KAPA) Stock Price & News - Syfe
Ambros deal would give Werewolf (NASDAQ: HOWL) investors rights to future sales of legacy drug assets - Stock Titan
German investor discloses stake in Werewolf Therapeutics (NASDAQ: HOWL) - Stock Titan
Werewolf Therapeutics (HOWL) Dips 1.43% to $0.97 as Tight Trading Range Sends Stock Toward Key SupportEarnings Miss Risk - dars.gov.et
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
CalciMedica, Inc. (CALC) Stock Price & News - Syfe
Werewolf Therapeutics Stock Price Forecast. Should You Buy HOWL? - StockInvest.us
Werewolf Therapeutics stock gains on merger scrutiny and trial progress - ad-hoc-news.de
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Lantern Pharma Inc. (LTRN) Stock Price & News - Syfe
Onconetix, Inc. (ONCO) Stock Price & News - syfe.com
Valion Bio, Inc. (VBIO) Stock Price & News - Syfe
Werewolf Therapeutics Completes Key Early Trial For WTX-124 In Hard-To-Treat Cancers - TipRanks
$HAREHOLDER ALERT: The M&A Class Action Firm Announce the Investigation of the MergerHOWL, HZO, TYFG and FULC - Sahm
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Werewolf, Ambros to Merge in All-Stock Deal - Contract Pharma
$HAREHOLDER ALERT: The M&A Class Action Firm Announce the Investigation of the MergerHOWL, HZO, TYFG and FULC - PR Newswire
Werewolf Therapeutics And Ambros Therapeutics Merge With $150 Million PIPE To Advance Phase III CRPS Drug Neridronate - Pulse 2.0
$HAREHOLDER ALERT: The M&A Class Action Firm Announce the Investigation of the MergerHOWL, HZO, TYFG and FULC - Morningstar
Werewolf (HOWL) Outlook: Moves 102.57% Up to $0.87 in the Latest Reading; Boundary Watch: $0.83 and $0.91 Define the Nearby Reference Levels at the CloseMoving Average Ribbon - vinanet.vn
Werewolf (HOWL) Outlook: Moves 102.57% Up to $0.87 in the Latest Reading; Boundary Watch: $0.83 and $0.91 Define the Nearby Reference Levels at the CloseMESA MA - siam.in
HOWL | Werewolf Therapeutics, Inc. Common FinancialsRevenue Breakdown - Quiver Quantitative
Ambros Therapeutics to merge with Werewolf Therapeutics in all-stock deal - Dealroom
Werewolf Therapeutics (NASDAQ:HOWL) Deal Changes Pipeline Focus - Kalkine Media
Werewolf Therapeutics Shares Surge Twofold After Ambros Merger, Investors Retain 6.8% Stake - TechStock²
Latham Watkins Advises on Oversubscribed Private Placement in Werewolf Ambros Merger Transaction - Latham & Watkins LLP
Werewolf Therapeutics, Inc. announced that it expects to receive $150 million in funding - marketscreener.com
Werewolf Therapeutics Strikes Reverse Merger With Ambros, Secures $150 Million for Rare Pain Drug - finance.biggo.com
Trending Stocks Today | Werewolf Therapeutics Shoots up 117.27% - Moomoo
Little-Known HOWL Stock Skyrockets 100% on Biotech Merger News - Yahoo Finance
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Watertown biotech agrees to reverse merger with Vivek Ramaswamy-backed startup - The Business Journals
Gold Moves Higher; US Composite PMI Surges In August - Benzinga
Werewolf and Ambros Therapeutics announce merger - The Pharma Letter
Werewolf Therapeutics (HOWL) Stock Soars 127% on Ambros Merger and $150M Financing Deal - Blockonomi
Werewolf Therapeutics stock soars on Ambros merger deal and $150 million PIPE - Quiver Quantitative
Why is Werewolf Therapeutics stock surging more than 100% today? By Investing.com - Investing.com Canada
Why is Werewolf Therapeutics stock surging more than 100% today? - Investing.com
Werewolf transforms into Ambros via reverse merger to support phase 3 push for rare disease drug - Fierce Biotech
Why Is Werewolf Therapeutics Stock Gaining Friday?Werewolf Therapeutics (NASDAQ:HOWL) - Benzinga
Israel Englander's HOWL Stock Soars on $500M DealWerewolf Therapeutics (NASDAQ:HOWL) - Benzinga
Werewolf Therapeutics to Merge and Rebrand as Ambros - TipRanks
Werewolf Therapeutics shares surge 120% after Ambros merger and $150 million financing - Yahoo Finance
HOWL Stock Whipsaws As One-Off Profit Meets Uncertain Future - StocksToTrade
Why Is Penny Stock Werewolf Therapeutics (HOWL) Up Today? - TipRanks
Werewolf (NASDAQ: HOWL) Ambros deal leaves holders with single-digit stake - Stock Titan
Werewolf Therapeutics to Merge With Ambros in Stock Deal; Raises $150 Million PIPE, Holders Locked Up - TradingView
Werewolf Therapeutics Inc Stock (HOWL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Werewolf Therapeutics Inc Stock (HOWL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| EVNIN LUKE | Director |
Jul 06 '26 |
Sale |
0.32 |
35,770 |
11,446 |
107,429 |
| MPM BioVentures 2014, L.P. | Shareholder |
Jul 06 '26 |
Proposed Sale |
0.34 |
96,873 |
32,976 |
0 |
| MPM BioVentures 2014 (B), L.P. | Shareholder |
Jul 06 '26 |
Proposed Sale |
0.34 |
6,459 |
2,199 |
0 |
| UBS Oncology Impact Fund, L.P. | Shareholder |
Jul 06 '26 |
Proposed Sale |
0.34 |
80,142 |
27,280 |
0 |
| MPM Asset Management LLC | Shareholder |
Jul 06 '26 |
Proposed Sale |
0.34 |
15,341 |
5,222 |
0 |
| MPM Asset Management Investors | Shareholder |
Jul 06 '26 |
Proposed Sale |
0.34 |
3,332 |
1,134 |
0 |
| MPM Oncology Innovations Fund, | Shareholder |
Jul 06 '26 |
Proposed Sale |
0.34 |
21,194 |
7,214 |
0 |
| MPM BioVentures 2014 (B), L.P. | Shareholder |
Jun 29 '26 |
Proposed Sale |
0.32 |
7,087 |
2,289 |
0 |
| MPM Asset Management LLC | Shareholder |
Jun 29 '26 |
Proposed Sale |
0.32 |
16,830 |
5,436 |
0 |
| MPM Oncology Innovations Fund, | Shareholder |
Jun 29 '26 |
Proposed Sale |
0.32 |
23,248 |
7,509 |
0 |
1.64%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):